An interventional study of Standard 6MWT and Gamified 6MWT in Neuromuscular Diseases in Children, sponsored by David Toupin. Recruiting at 1 site in United States. Open to participants aged 6 Years to 12 Years. Per ClinicalTrials.gov, last updated 2026-07-27.
Sponsored by David Toupin · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 120 studies in Neuromuscular Diseases with a site in United States — 29 open to participants now, 39 under way, 4 of them phase 3. Neuromuscular Diseases · United States.
Among the 120 studies in Neuromuscular Diseases with a site in United States, this one is the 53rd largest by planned enrollment of the 72 interventional ones that give a count, is one of 10 that started in 2026, is one of 23 with no phase, reaches primary completion later than 17 of the 38 other live ones, and was the 108th registered.
361 studies on the registry are indexed under Neuromuscular Diseases; 96 are open to participants now.
Browse Neuromuscular Diseases studies →29 of the 120 studies in Neuromuscular Diseases with a site in United States are open now. Recruiting first, the newest first:
Virginia Commonwealth University · Sites in United States
Ages 18–70
University of Pennsylvania · Sites in United States
Ages 18+
Dyne Therapeutics · Sites in United States
Ages 4–18 · Men only
Northwestern University · Sites in United States
Ages 18+
AskBio Inc · Sites in United States
Ages 18–65
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 69 Neuromuscular Diseases studies recruiting now, 39 (57%) set no upper age limit and 22 (32%) stop at 75 or younger; 35 take children under 18; 16 take healthy volunteers.
This study: 6 Years to 12 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
120 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 26 · Phase 3 20
First in 1984; this study’s year is marked. 10 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 30 across 204 interventional studies indexed under Neuromuscular Diseases.
Median enrollment 48 across the 72 interventional studies, 82 across the 46 observational. Of the 77 that completed or were terminated, 28 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
53 of 120 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with David Toupin as lead sponsor.
David Toupin has 1 study filed under Neuromuscular Diseases — fewer than ten, so there is no comparison to draw.
14 of the studies in Neuromuscular Diseases with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03797183University of Colorado, DenverGenesis Electrical Impedance Tomography (EIT): A Preliminary Study | 2026-11 |
| NCT06970522Shirley Ryan AbilityLabWearable Sensors to Detect Atypical Muscle Activation in Young Infants | 2026-12-31 |
| NCT00390104Boston Children's HospitalMolecular Analysis of Patients With Neuromuscular Disease | 2026-12-31 |
| NCT06185764Vertex Pharmaceuticals IncorporatedA Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1) | 2027-02-02 |
| NCT07223632Vanda PharmaceuticalsTreatment of Charcot-Marie-Tooth Disease, Axonal, Type 2S (CMT2S) in an Individual Patient | 2027-03 |
Add all 14 to your calendar (.ics) → With an account.
Among the 120 studies in Neuromuscular Diseases with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this study is to learn if adding a game to the 6-minute walk test for children with neuromuscular disorders will increase enjoyment and motivation to complete the test.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
child carries a Radio-frequency identification (RFID) tag to scan at each lap, watching avatar level up.
Other: Gamified 6MWT
no game; same verbal cue every minute
Other: Standard 6MWT
ATS-standard instructions, no electronic system; Conducted in hallway measuring total length of 90ft (27.4 meters). Patients will walk down-and-back. A seated rest period of ≥10 min separates the two tests to minimize fatigue carry-over.
identical course but child carries a RFID tag; at each lap the child taps an on an RFID reader, awarding a point and leveling-up an on-screen avatar; Conducted in hallway measuring total length of 90ft (27.4 meters). Patients will walk down-and-back.A seated rest period of ≥10 min separates the two tests to minimize fatigue carry-over.
Change in 6 minute walk distance
Participants will walk back and forth in the clinic hallway for 6 minutes and distance will be recorded in meters
Time frame: Baseline and post intervention (approximately 20 minutes)
Change in Children's OMNI Rate of Perceived Exertion (RPE) Scale
The OMNI RPE scale is a visual and numerical tool from 0-10 that helps individuals subjectively gauge the intensity of walking or running activity, with 0 representing no effort and 10 being maximal exertion.
Time frame: Baseline and post intervention (approximately 20 minutes)
Change in Physical Activity Enjoyment Scale (PACES)
The Physical Activity Enjoyment Scale (PACES) consists of 8 questions scored on a scale from 1 to 7, with a maximum score of 56 and a minimum score of 8. Higher scores indicate greater enjoyment of physical activity.
Time frame: Baseline and post intervention (approximately 20 minutes)
Recruitment Rate
percent of eligible participants successfully recruited in the study
Time frame: 9 months
Test completion rate
number of walk tests successfully completed compared to overall number of walk tests
Time frame: 9 months
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2026 (actual). Primary completion is estimated for Jun 2027, 12 months after the start.
Of 75 non-industry interventional studies with no phase under Neuromuscular Diseases, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 47. This study's planned 12 months is below that.
Counting every sponsor, half of 84 studies reached it within 25 months; a quarter within 12 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.